ELUTYX™ proprietary bioresorbable hydrogel - based formulation technology

Search documents
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
Globenewswire· 2025-07-29 11:00
Core Viewpoint - Ocular Therapeutix, Inc. is set to discuss its recent business progress and financial results for Q2 2025 in an upcoming conference call on August 5, 2025 [1]. Group 1: Company Overview - Ocular Therapeutix, Inc. is a biopharmaceutical company focused on redefining the retina experience [3]. - The company is developing AXPAXLI™ (OTX-TKI), an investigational product for retinal disease, currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) [3]. - Ocular's pipeline includes DEXTENZA, an FDA-approved corticosteroid for treating ocular inflammation and pain post-surgery, and OTX-TIC, an investigational product in Phase 2 trials for open-angle glaucoma or ocular hypertension [4]. Group 2: Conference Call Details - The conference call and webcast will take place on August 5, 2025, at 8:00 AM ET [2]. - Participants can join via U.S. dial-in at 1-877-407-9039 or international dial-in at 1-201-689-8470 [2]. - The live and archived webcast will be accessible on the Ocular Therapeutix website for at least 30 days [2].
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
Globenewswire· 2025-04-28 11:00
Core Viewpoint - Ocular Therapeutix, Inc. plans to release its first quarter 2025 financial results on May 5, 2025, at 7:00 AM Eastern Time, and will not hold a conference call for this quarter, resuming calls for the second quarter 2025 [1]. Company Overview - Ocular Therapeutix, Inc. is a biopharmaceutical company focused on redefining the retina experience [3]. - The company’s investigational product AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI) is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) [3]. - Ocular's pipeline includes DEXTENZA, an FDA-approved corticosteroid for treating ocular inflammation and pain post-surgery, and PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is in Phase 2 clinical trials for open-angle glaucoma or ocular hypertension [4].